Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 2/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17099351 | 0.83 | S1PR5 (0.53) | S1PR5S1PR4S1PR1S1PR3LTA4H | |
| SCHEMBL17108217 | 0.79 | KDM4E (0.51) | KDM4E | |
| SCHEMBL17099418 | 0.78 | FAAH (0.54) | S1PR5S1PR4S1PR1S1PR3LTA4H | |
| SCHEMBL17316361 | 0.73 | SSTR5 (0.46) | SSTR5HTR2AALDH1A1KDM4E | |
| SCHEMBL18117051 | 0.73 | S1PR5 (0.71) | S1PR5S1PR4S1PR1S1PR3LTA4H | |
| SCHEMBL28669075 | 0.72 | S1PR5 (0.48) | S1PR5S1PR4S1PR1S1PR3LTA4H | |
| SCHEMBL16695229 | 0.71 | S1PR5 (0.65) | S1PR5S1PR4S1PR1S1PR3LTA4H | |
| SCHEMBL4795270 | 0.71 | S1PR5 (0.62) | S1PR5S1PR4S1PR1S1PR3LTA4H | |
| SCHEMBL4795273 | 0.71 | S1PR5 (0.62) | S1PR5S1PR4S1PR1S1PR3LTA4H | |
| SCHEMBL16301219 | 0.71 | S1PR5 (0.77) | S1PR5S1PR4S1PR1S1PR3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | SSTR5 2070/4885S1PR5 2295/4885S1PR4 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.